Taxon Therapeutics
Recombinant Therapeutic Proteins for Rare Autoimmune Diseases
Company Overview
Snapshot
Founded in June 2020 by David Cogen and Dobroslav Melamed, Taxon Therapeutics operates with 1–10 employees. The company is currently in a pre-funding stage, focusing on the development of recombinant therapeutic proteins. In October 2020, Taxon Therapeutics entered into a preliminary agreement with Mabion regarding MabionCD20.
Business overview
Taxon Therapeutics is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins for rare autoimmune diseases with significant unmet medical needs. Its core product, TAX-01, is engineered to treat adults suffering from autoimmune hemolytic anemia, a severe and rare blood disorder characterized by the destruction of red blood cells by the body's own antibodies. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its drug discovery and development efforts.
Strategic signal
In October 2020, Taxon Therapeutics established a preliminary agreement with Mabion concerning MabionCD20. This collaboration signals early strategic validation for Taxon Therapeutics' therapeutic approach and potential for future partnerships in the biopharmaceutical space, indicating a focus on leveraging external expertise for product development.
Log in to access full profile ›Company Intelligence Q&A
- What is Taxon Therapeutics' primary focus?
- Taxon Therapeutics is focused on the development and commercialization of recombinant therapeutic proteins for rare autoimmune diseases with unmet medical needs.
- Which specific product is Taxon Therapeutics developing?
- Taxon Therapeutics is developing TAX-01, a product designed for the treatment of adults with autoimmune hemolytic anemia.
- When was Taxon Therapeutics founded and by whom?
- Taxon Therapeutics was founded in June 2020 by David Cogen and Dobroslav Melamed.
- What was a significant early strategic development for Taxon Therapeutics?
- In October 2020, Taxon Therapeutics entered into a preliminary agreement with Mabion regarding MabionCD20.
- What is the current status of Taxon Therapeutics?
- Taxon Therapeutics is currently non-active, having ceased operations in April 2024.